REFERENCE
Miksad RA, Schnipper L, Goldstein M.Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? Journal of Clinical Oncology 25: 4506-4507, No. 28, 1 Oct 2007
Rights and permissions
About this article
Cite this article
Erlotinib + gemcitabine of no value in pancreatic cancer. Pharmacoecon. Outcomes News 539, 5 (2007). https://doi.org/10.2165/00151234-200705390-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705390-00006